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ABSTRACT
Growing evidence implicates impairment of autophagy as a candidate pathogenic mechanism in the
spectrum of neurodegenerative disorders which includes amyotrophic lateral sclerosis and frontotemporal
lobar degeneration (ALS-FTLD). SQSTM1, which encodes the autophagy receptor SQSTM1/p62, is genetically
associated with ALS-FTLD, although to date autophagy-relevant functional defects in disease-associated
variants have not been described. A key protein-protein interaction in autophagy is the recognition of a lipid-
anchored form of LC3 (LC3-II) within the phagophore membrane by SQSTM1, mediated through its LC3-
interacting region (LIR), and notably some ALS-FTLD mutations map to this region. Here we show that
although representing a conservative substitution and predicted to be benign, the ALS-associated L341V
mutation of SQSTM1 is defective in recognition of LC3B. We place our observations on a firm quantitative
footing by showing the L341V-mutant LIR is associated with a »3-fold reduction in LC3B binding affinity and
using protein NMR we rationalize the structural basis for the effect. This functional deficit is realized in motor
neuron-like cells, with the L341V mutant EGFP-mCherry-SQSTM1 less readily incorporated into acidic
autophagic vesicles than the wild type. Our data supports a model in which the L341V mutation limits the
critical step of SQSTM1 recruitment to the phagophore. The oligomeric nature of SQSTM1, which presents
multiple LIRs to template growth of the phagophore, potentially gives rise to avidity effects which amplify
the relatively modest impact of any single mutation on LC3B binding. Over the lifetime of a neuron, impaired





ALS and FTLD are devastating and invariably fatal neurode-
generative diseases thought to belong to the same clinicopatho-
logical spectrum of disorders. Both sporadic and familial forms
occur with more than 30 different genes linked to ALS-FTLD
and showing different degrees of causality from major effects
through to genetic predisposition. A number of different patho-
genic mechanisms have been proposed with growing evidence
suggesting that autophagy may be disturbed in ALS-FTLD;
post mortem analyses of patient tissue reveal increased num-
bers of autophagosomes1,2 and several disease-associated pro-
teins are regulators of autophagy. More specifically, mutations
affecting the autophagy cargo receptors UBQLN2/ubiquilin-2,
OPTN/optineurin and SQSTM1/p62 have been reported in
ALS-FTLD families.3 Very recently mutations affecting the
gene encoding TBK1 (TANK-binding kinase 1), a kinase which
targets both OPTN and SQSTM1 thus linking the proteins in a
common pathway, have been identified as a cause of familial
ALS-FTLD.4,5 Autophagy is a critical pathway for the removal
of damaged and aggregation-prone proteins and organelles; for
example, in the ALS context mediating the turnover of aggre-
gated forms of the major pathological protein TARDBP (TAR
DNA binding protein),6 and is essential for neuronal survival.7,8
ALS-FTLD-associated mutants of the autophagy receptor
OPTN are defective in the selective degradation of mitochon-
dria via autophagy9,10 with a mechanism that may involve com-
promised maturation of autophagosomes.11 Further, depletion
of optn in zebrafish is associated with a motor axonopathy,
which is phenotypically similar to a model of ALS expressing
mutant SOD1.12 Similarly, numerous missense and truncating
mutations affecting the SQSTM1 gene, which encodes the
SQSTM1 protein, have over the past 4 years been identified in
patients with ALS and FTLD.13 Curiously SQSTM1 mutations
are also found in patients with the skeletal disorder Paget dis-
ease of bone (PDB), including some variants that are common
to both disease phenotypes13 and polymorphisms in other
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autophagy genes have recently been associated with PDB in a
Spanish cohort.14 SQSTM1 is a multidomain scaffold protein
involved in various signaling pathways and more recently char-
acterized as a cargo receptor for ubiquitin-mediated auto-
phagy.15 At least in osteoclasts derived from mice expressing
the equivalent of a PDB and ALS-associated mutant
SQSTM1P392L, markers indicative of dysregulation of autoph-
agy are evident.16 In zebrafish, knockdown of Sqstm1 is associ-
ated with a locomotor phenotype that can be rescued by the
autophagy activator rapamycin, as well as wild-type human
SQSTM1 but not the P392L mutant, suggesting that changes in
SQSTM1-mediated autophagy are linked to the phenotype.17
ALS-FTLD-associated missense mutations of SQSTM1 are dis-
tributed in different functional domains throughout the primary
sequence of the 440-residue protein13 and notably a subset of these
mutations map to the LC3-interacting region (LIR) of the pro-
tein.18 The LIR is a critical motif that allows SQSTM1 to couple to
the developing phagophore through the recognition of lipid-
anchored LC3 proteins (mammalian family of orthologs of yeast
Atg8), within the phagophore membrane. This highly conserved
region is located between amino acids 321 to 342 of human
SQSTM115,19 with structural analyses indicating that the motif
DDDWTHL (corresponding to residues 335 to 341) is directly
involved in the interaction with LC3. One particular SQSTM1
mutation, an L341V missense mutation identified in a Chinese
patient with late-onset sporadic ALS,18 is of interest since it affects
a residue within the LIR of SQSTM1. Indeed the crystal structure
of an LIR peptide (residues 332 to 342) in complex with LC3B
revealed that L341 forms direct contacts with LC3B within the sur-
face binding cleft.19 Consistent with this observation an artificial
mutation at the same position (L341A) in the 332 to 342 LIR pep-
tide results in significantly reduced SQSTM1-LC3B complex in
qualitative protein binding assays,19 as is also the case in a slightly
longer LIR peptide (332 to 347).20 Here we show that the ALS-asso-
ciated L341V mutation, although previously predicted to represent
a benign substitution,18 actually exerts a quantifiable effect on
LC3B binding in vitro and affects SQSTM1 recruitment into acidic
autophagic vesicles in living cells. Our data supports a model in
which certain SQSTM1mutations limit a critical step in autophagy
and provides important functional evidence for a role of the auto-
phagic pathway in ALS-FTLD.
Results
The L341V mutation affects the recognition of LC3B
by SQSTM1
The L341Vmissense mutation of SQSTM1, identified in a late-onset
sporadic ALS patient, represents a conservative amino acid change,
which has previously been predicted (based on SIFT and PolyPhen-2
prediction tools) to represent a benign substitution.18 We first used
biochemical approaches to examine any impact of the L341V muta-
tion on well-characterized protein-protein interactions relevant to
SQSTM1-mediated autophagy. Protein affinity isolation assays in
which interaction partners LC3Bor ubiquitin covalently immobilized
on beads were used to capture recombinant GST-SQSTM1 fusion
proteins, followed by detection of bound protein by western blotting.
The same assay has previously been used to demonstrate ubiquitin-
binding defects associated with PDB-linked UBA domain mutations
of SQSTM1.21 Consistent with its location within the SQSTM1 LIR,
defined by the 338 to 341 WXXL motif, we found that the L341V
mutant selectively reduced capture of GST-SQSTM1 by LC3B, rela-
tive to the wild type, whereas binding to ubiquitin was unaffected
(Fig. 1 and Fig. S1). As a control the previously characterized PDB-
linked UBA domain SQSTM1 mutation, G425R (SQSTM1G425R),21
also now reported in cases of ALS,22 was found to selectively impact
only on ubiquitin-binding, with no evidence of this mutation affect-
ing LC3B recognition. Thus, L341V exhibits a domain-specific effect
on the interaction of SQSTM1with LC3B in vitro.
ESI-MS confirms weaker binding of the L341V mutant LIR
to LC3B
We next used a native ESI-MS approach, where under carefully
optimized nondenaturing conditions noncovalent protein com-
plexes representative of solution binding can be maintained in
the gas phase, in order to determine the effects of the L341V
mutation on LC3B recognition by the LIR. Synthetic peptides
with LIR (L341V) or without the mutation (WT LIR), repre-
senting an extended LIR sequence (residues 332 to 351) com-
pared to those previously characterized in structural detail (332
to 34219 and 332 to 34720), were generated by solid-phase syn-
thesis. Mass differences associated with the leucine to valine
substitution meant that multiply charged species of the 2 pepti-
des could be readily distinguished by ESI-MS (Fig. 2A). We set
up a competitive binding mixture including 5 mM of purified
LC3B along with equimolar concentrations of the 2 LIR pepti-
des (i.e., a mixture of 1:1:1) and assessed complex formation by
ESI-MS. Notably, peaks in the spectra showed evidence for a
more significant population of the LC3B-WT LIR complex
compared to LIR (L341V) (Fig. 2B, 2C complex of free LIRs
and 9C complex of LIR-LC3B complexes indicated in lower
panel) indicative of a reduction in binding affinity for the
mutant peptide. Under these conditions the abundance ratio of
LC3B bound to WT LIR compared to LIR (L341V) was 3:1,
entirely consistent with a reduced binding affinity of the
mutant LIR.
Figure 1. ALS-FTLD-associated SQSTM1 mutations impact on the recognition of LC3B (SQSTM1L341V) or ubiquitin (SQSTM1G425R) in vitro. Mutations as indicated (or wild
type, WT) were introduced into the full-length GST-SQSTM1 sequence and affinity isolation assays (LC3B and ubiquitin on beads) were performed at 37C. Bacterial lysates
containing the GST-SQSTM1 fusions were incubated with glutathione- (G), control- (C), LC3B (LC3), and ubiquitin-Sepharose (Ub) beads and captured proteins were
detected by western blotting (anti-SQSTM1 antibodies). A representative blot is shown; see Fig. S1 for quantification of 3 independent experiments.
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Quantifying the magnitude of the effects of the L341V
mutation on LC3B binding
We used isothermal titration calorimetry (ITC) to corroborate
the MS data and determine binding affinities (Kd). Separate
titrations were performed with starting concentration of the
LC3B at 15 mM, with addition of aliquots of the LIR peptides
(WT LIR or LIR (L341V) at 350 mM, at 25C in 25 mM phos-
phate buffer, 150 mM NaCl, pH 7.5). High quality binding iso-
therms (Fig. 3) fitted well to a one-site binding model with a Kd
value for WT LIR in the low mM range (3.2 § 1.1 mM). How-
ever, the LIR (L341V) peptide was associated with a »3-fold
reduction in LC3B binding affinity (10.9 § 1.1 mM) and a sub-
stantially reduced enthalpy of interaction. The latter would
appear to reflect possible steric effects and unfavorable van der
Waals contacts from forcing a ‘square peg into a round hole.’
These binding affinities are within the same order of magnitude
as previously published affinities from Novak et al.23 which use
a similar-length peptide but covering a different set of residues
around the LIR (residues 321 to 342).
NMR reveals the structural basis for the effects
of the L341V mutation on LC3B recognition
To understand the mechanism for impairment of binding of
the LIR (L341V) at the molecular level we used NMR studies at
800 MHz to map differences in the binding interactions of
LC3B, using the same WT LIR and LIR (L341V) peptide
sequences used for MS and ITC studies. We first carried out an
extensive amide backbone NMR assignment for LC3B (> 95%
assignment of the nonprolyl residues) using double-isotope
labeling with 13C/15N and a combination of 3D heteronuclear
NMR spectra using well established methodologies (see
Methods; Fig. S2, gray). Subsequently, we were able to use the
sensitivity of 1H/15N-HSQC spectra of the assigned amide NHs
Figure 2. ESI-MS indicates weaker binding of the LIR (L341V) to LC3B compared to WT LIR. (A) Native ESI-MS spectrum of an equimolar mixture of WT LIR and LIR (L341V)
peptides (5 mM, residues 332 to 351). (B) LIR peptide mixture titrated with 5 mM LC3B. Top, full spectrum indicating free LIR (gray filled circle, mixture of WT LIR and LIR
[L341V]), free LC3B and LC3B-LIR complexes of indicated (multiple) charge states. Below, zoomed-in spectra showing m/z values of the free and bound LIR complexes at
the indicated charge states.
Figure 3. Isothermal titration calorimetry (ITC) binding isotherms from titrating
LC3B with LIR peptides at 25C. Binding isotherms were fitted to a one-site binding
model and Kd values determined. Starting concentration of the LC3B was approxi-
mately 30 mM, and of LIR peptide (residues 332 to 351) stocks approximately
350 mM. Black diamond, LIR (L341V); gray circle WT LIR.
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at the individual residue level to map the perturbations to LC3B
associated with ligand (LIR) binding (Fig. 4, Fig. S2, green and
blue). Titration studies with WT LIR revealed significant
changes to protein chemical shifts (> 0.5 ppm) for nearly
20 key residues; a subset of 9 of these demonstrated perturba-
tions of > 1.0 ppm (Fig. 5A) indicative of substantial structural
re-organization around the surface cleft to accommodate the
bound ligand. These residues can be mapped to the surface of
LC3B (Fig. 5C) and correspond very clearly with those identi-
fied as LIR contact residues in the X-ray structure of the LC3B-
LIR (332 to 342) complex.19 Of particular note was the use
of a shorter LIR-containing peptide in the X-ray studies
(SGGDDDWTHLSS versus SGGDDDWTHLSSKEVDPSTG
used here). Given that NMR CSP effects were observed over a
substantial number of LC3B residues both in direct contact,
and in some cases on the more remote nonbinding face, we
compared NMR data with a truncated LIR peptide of only
11 residues (amino acids 335 to 345). The 2 titrations with the
WT LIR-containing motifs highlighted a few small differences
(data not shown), however, the largest perturbations were
quantitatively very similar, indicating that the C-terminally
extended peptide sequence used in our studies, which accom-
modates the additional VDPSTG motif corresponding to the
KEAP1 interaction region (KIR), forms no additional signifi-
cant interactions across the surface of LC3B.
We repeated the titration experiments with LIR (L341V) in
the longer peptide sequence (332 to 351) and observed CSP
effects of similar magnitude to WT LIR, showing the same
extensive interaction (data not shown). By taking the difference
in CSP effects between WT LIR and LIR (L341V) sequences we
could readily identify 8 residues that were substantially different
between the 2 complexes, with the largest effects involving V33,
F52, L53, V54 and R70 (Fig. 5B). When these were specifically
highlighted on the LC3B protein (Fig. 5D) they correlated
remarkably closely with those constituting the binding cleft in
proximity to L341. The perturbations demonstrate that binding
of the mutant sequence is associated with some reorganization
of the pocket to accommodate the different steric demands of
the b-branched valine residue. We modeled the L341V substitu-
tion (data not shown), and observed significant steric clashes for
all side chain rotamers of the substituted valine side chain, con-
sistent with some loss of binding complementarity, leading to
reduced affinity.
Functional effects of the L341V mutation in a cellular
context
To determine whether the L341V mutation affects autophagy
in living cells we made use of an mCherry-EGFP double-tagged
SQSTM1 construct which allows acidic autophagic vesicles to
be distinguished from neutral SQSTM1-positive inclusion bod-
ies and autophagosomes.15 When ectopically expressed in cells
SQSTM1 can incorporate into cytoplasmic bodies with a simi-
lar phenotype to those observed when cells are stained for the
endogenous protein.24 The inclusion bodies represent non-
membrane enclosed structures whereas the autophagosomes
are membrane-limited; upon live cell imaging of both struc-
tures, red and green fluorescence (combined yellow) can be
detected as each represent pH neutral microenvironments.
However, following fusion of phagophores with lysosomes the
EGFP (green) signal is quenched in the resulting acidic milieu,
and only red fluorescence is detected, allowing transit of ectopi-
cally expressed SQSTM1 from phagophores to acidic autopha-
gic vesicles to be monitored.
Previous studies demonstrate that deletion of the LIR strongly
reduces the ability of SQSTM1 to be recruited into phagophores
and subsequently acidic vesicles.15 To assess the impact of the
more subtle L341V missense mutation, we introduced this
change in to the mCherry-EGFP-SQSTM1 construct and tran-
siently expressed this in the motor neuron-like cell line NSC-34.
Notably endogenous levels of SQSTM1 are previously reported
to be low (almost undetectable) in these cells.25 However, our
more rigorous analysis using different SQSTM1 antibodies
(Fig. S3) indicated that although NSC-34 cells do appear to
Figure 4. NMR titrations indicate selective perturbations of LC3B residues upon binding of LIR peptides. (A) 1H-15N-HSQC spectrum of LC3B (0.25 mM dark gray) overlaid
with the spectrum of the complex of LC3B with WT LIR (0.5 mM blue, residues 332 to 351) (ratio of 1:2) showing extensive chemical shift perturbations (CSPs) across the
spectrum induced by ligand binding at 298 K; (B) Expansion of the region highlighted in (A) showing overlap between the spectrum of LC3B (dark gray), LC3BCWT LIR
(blue) and LC3B C LIR (L341V) (green) illustrating a number of key residues within the LIR binding pocket that are perturbed to different extents by the WT LIR and LIR
(L341V). Arrows identify the shifts of V33, F52 and V54 in the 2 complexes, while the majority of other residues show only small differences between the spectra of the
2 complexes (overlap of blue and green peaks), demonstrating selective effects on residues in direct contact with the LIRs.
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express lower steady-state levels of SQSTM1 than other lines
(adventitiously limiting the contribution of endogenous protein
to any observed phenotype) these levels are not unusually low.
Further, levels of endogenous SQSTM1 and LC3B increased in
response to bafilomycin A1 (BafA1) treatment with a similar
profile to HeLa cells (Fig. S3) indicating NSC-34 have normal
autophagy machinery. We confirmed that steady-state levels of
transfected mCherry-EGFP-SQSTM1 (wild type and L341V)
were similar by western blot (Fig. S4). In cells 48 h after transfec-
tion with wild-type mCherry-EGFP-SQSTM1 we noted obvious
yellow and red structures (Fig. 6),26 with the red acidic vesicles
most prominent within the characteristic short neurites. Treat-
ment with the autophagy inhibitor BafA1 visually reduced the
number of red acidic structures (Fig. 6), which was quantified by
determining the increase in the mean Pearson correlation coeffi-
cient (PCC) value of mCherry and EGFP overlap (Fig. 7). In
contrast, in cells transfected with mutant mCherry-EGFP-
SQSTM1L341V there were visibly fewer red acidic vesicles in the
absence of BafA1 (Fig. 6), evidenced by a mean PCC value
which was greater than that for the wild type (Fig. 7). Treatment
of the L341V mutant-expressing cells with BafA1 further
increased the mean PCC value (Fig. 7), indicating that the cells
were still functional with respect to autophagy, consistent with
reversal of the mutant phenotype (reduction in PCC values)
observed following treatment of mutant-expressing cells with the
autophagy-enhancer rapamycin (Fig. 7). We also confirmed the
L341V mutant phenotype in an additional neuronal cell
line, mouse neuroblastoma Neuro-2a cells (Fig. S5); although the
difference in mean PCC values between wild type- and L341V
mutant-expressing cells was smaller in these cells this was still
statistically significant. Overall these data are consistent with
mutant mCherry-EGFP-SQSTM1L341V being less readily incor-
porated into acidic vesicles than the wild type.
Discussion
Our findings, using multiple independent approaches, of defec-
tive LC3B recognition by an ALS-associated variant of
SQSTM1, and a reduced ability of the mutant protein to incor-
porate into acidic autophagic vesicles in living cells, adds to the
accumulating evidence that disturbances in autophagy may
underlie some cases of ALS-FTLD. Other studies to date have
presented histological1,2 and genetic3 evidence for such a dis-
turbance, but importantly we now add functional evidence by
describing on a firm quantitative and structural footing a defect
in an autophagy-relevant protein-protein interaction. Specifi-
cally we confirm that the ALS-associated L341V mutation of
SQSTM1 exerts a quantifiable effect on LC3B binding in vitro.
While a 3-fold reduction in binding affinity may appear mod-
est, we suggest that over the lifetime of a neuron it may become
biologically significant (see later). Indeed the change in binding
affinity is sufficient to give a clear autophagy phenotype in our
NSC-34 cell model as well as in Neuro-2a cells, i.e., two differ-
ent neuronal cell lines, one of which is motor neuron-like. In
this cellular context it is also possible that post-translational
modification (e.g. phosphorylation of the LIR27) may directly
Figure 5. Chemical shift mapping of the binding of the WT LIR and LIR (L341V) peptides (residues 332 to 351) to 15N-LC3B. (A) Chemical shift mapping of the WT LIR.
Weighted chemical shift pertubation (CSP) data showing the residues of 15N-LC3B (0.25 mM) that are perturbed upon WT LIR binding at a final ratio of 1:2 (LC3B:LIR) at
298 K. All CSPs above 1.0 are indicated. (B) Difference in CSP effects between WT LIR and LIR (L341V) sequences from NMR titrations at a final ratio of 1:2 (LC3B:LIR) at
298 K. The indicated residues showed CSPs that are substantially different between the 2 complexes (greater in the WT LIR). (C) Representation of binding surface of
LC3B with WT LIR, generated by highlighting residues determined from NMR chemical shift mapping experiments. LC3B residues in blue showed the greatest CSP values.
Backbone representation of the LIR peptide also indicated (residues DDDWTHLS, 335 to 342 shown). (D) Residues showing substantially different CSPs from the NMR titra-
tions of LC3B with WT LIR compared to LIR (L341V), highlighted on the LC3B structure. Note the close correlation with the binding cleft in proximity to L341 of the LIR
peptide (site of L341V indicated).
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or indirectly exaggerate the differences in binding affinities
between wild-type and mutant sequences. However, a further
important consideration in this respect is the structural organi-
zation of SQSTM1 in forming flexible oligomeric assemblies
critical to its functional role in autophagy. Recent cryo-EM
studies have established that the N-terminal (100 residue) PB1
domain of SQSTM1 and nearby sequences (also associated
with ALS-related mutations) drive the formation of polymeric
helical SQSTM1 filaments.28 These SQSTM1 filaments are pro-
posed to present multiple LC3 binding sites to aid the growth
of the phagophore onto the filaments. Thus, we speculate that
avidity effects between multiple LIRs on the surface of the
assembled SQSTM1 scaffold and membrane-tethered LC3B
could provide a mechanism for amplifying any small detrimen-
tal effects on binding affinities from individual LIR mutations
and these effects are ultimately manifested as a clear phenotype
in the NSC-34 and Neuro-2a cell models. Similarly, in our in
vitro affinity isolation with GST-SQSTM1, dimerization of
GST may further promote avidity effects. Notably in the NSC-
34 cells rapamycin is able to rescue the effects of the mutation
on incorporation of SQSTM1 into phagophores, via currently
undefined changes downstream of MTOR-dependent signaling,
which must overcome the relatively modest reduction in LC3B-
binding activity associated with the mutation; this observation
supports the notion that autophagy-enhancing strategies may
be beneficial in some cases of ALS.
The particular ALS-associated variant of SQSTM1 that we
analyzed, identified in a late-onset sporadic ALS patient, is a
Figure 6. Imaging of NSC-34 cells transfected with mCherry-EGFP-SQSTM1 constructs. mCherry-EGFP-SQSTM1 constructs (wild type [WT] or L341V mutant) were tran-
siently transfected into NSC-34 cells. Thirty-two h post-transfection cells were left untreated or treated with BafA1, 20 nM and 16 h later visualized on a DeltaVision micro-
scope. Images shown are representative of cellular phenotypes of the vast majority of cells in each treatment group. Scale bars: 10 mm. (RHS) intensity plots along the
lines as indicated on the extended focus cell images showing co-incidence of EGFP and mCherry fluorescence.
Figure 7. Quantification of colocalization of mCherry-EGFP-SQSTM1 transfected
NSC-34 cells. Mean Pearson Correlation Coefficient (PCC) values of mCherry and
EGFP overlap taken from a minimum of 50 cells per condition (NSC-34 cells trans-
fected with mCherry-EGFP-SQSTM1 constructs) over a minimum of 3 independent
experiments, with SEM indicated. Note the significant increase in PCC value in the
wild-type-expressing cells treated with BafA1 and in the L341V mutant-expressing
cells compared to wild type without BafA1 treatment (P values as indicated).
When used cells were treated with 20 nM rapamycin 3 h before imaging (CRap).
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conservative amino acid change (leucine to valine) which has
previously been predicted by web-based prediction tools to rep-
resent a benign substitution.18 Such a prediction probably arose
since L341 of SQSTM1, although highly conserved in mam-
mals, in Xenopus is substituted by the valine amino acid found
in the ALS patient. However it is not unusual for a deleterious
missense mutation in one species to be found as the wild-type
residue in orthologs of other species without effecting on the
fitness of the latter; this can occur as a result of the phenome-
non termed ‘Compensated Pathogenic Deviations’.29 Our func-
tional studies are therefore a reminder of the caveats of relying
on prediction programmes alone to establish the pathogenicity
of variants of unknown clinical significance. It will be of partic-
ular importance in the future to extend our studies to other
ALS-associated LIR mutations of SQSTM1 similarly suggested
to be benign. For example, an aspartic acid to glutamic acid
(D337E) mutation, also identified in a Chinese patient with
sporadic ALS,18 is predicted to be benign. Although the artifi-
cial mutation of aspartic acid to alanine (D337A) reveals little
effect on LC3B binding in affinity isolation assays using GST-
tagged LIR sequences,20 subtle but biologically-relevant effects
on LC3B recognition cannot be discounted. It is also notable
that many ALS-associated SQSTM1 mutations affect other
functional regions outside of the LIR that have significance for
autophagy, for example the UBA domain and PB1 domains
which are both necessary for successful cargo delivery to the
phagophore.3,15 Therefore, while LIR mutations appear to limit
the crucial step in selective autophagy of cargo receptor delivery
to the phagophore, a model emerges where other SQSTM1
mutations may have an impact on, for example, cargo recogni-
tion, and the ability of the PB1 domain to regulate SQSTM1
assembly into the larger helical scaffolds required to nucleate
the growing autophagosomal membrane.28 The role of avid
interactions in amplifying the effects of individual mutations is
intriguing in the light that SQSTM1 not only forms oligomeric
scaffolds, but that the UBA domain also forms a dimeric struc-
ture that also plays a role in regulating binding to ubiquitinated
cargo.30 In a similar context Lee et al. have recently highlighted
how other ALS-associated genetic alterations may impact on
different steps of autophagy, for example, vesicle nucleation
(SOD1), autophagosome trafficking (DCTN [dynactin],
DYNC1H1 [dynein cytoplasmic 1 heavy chain1], SOD1) and
phagophore-lysosome fusion (VCP [valosin containing pro-
tein], CHMP2B [charged multivesicular body protein 2B]).31
Dysregulation of autophagy in ALS-FTLD may represent a
wider mechanistic aberration that crosses over between other
mutational and perhaps even nonmutational causes. The
notion of autophagic dysfunction is entirely consistent with the
emerging thinking that ‘lysosomal dysfunction’ underlies a
range of neurodegenerative disorders including dementia with
Lewy bodies and frontotemporal dementia (FTD, the most
common FTLD syndrome), supported from recent genome-
wide association study (GWAS) analyses.32,33
We speculate that subtle effects on autophagy associated
with SQSTM1 (and other) variants predispose neurons to a vul-
nerability, which over time may become exposed by, for exam-
ple, an age-related decline in autophagy pathway activity34,35 or
‘second-hit’ in another protein clearance pathway such as the
ubiquitin-proteasome system.6,36 Causal mutations in other
autophagy-related ALS-linked genes likely have more domi-
nant effects. In this regard, Hardy and coworkers have recently
speculated that motor neurons and cortical pyramidal neurons
exist close to the edge of a ‘catastrophic cliff.’ Any events which
expose neuronal vulnerability, for example mutations or other
factors impacting on protein quality control, could be sufficient
to push the cell ‘over the cliff’ i.e., ultimately resulting in cell
death. In other words, subtle variants such as the L341V muta-
tion of SQSTM1, over the lifetime of a neuron affect protein
quality control, which in combination with other insults ulti-
mately tip the balance from cell survival toward cell death. If
the L341V mutant SQSTM1 were to accumulate over time
(due to impaired turnover) then it would also have the potential
to impact on the clearance of ubiquitinated proteins destined
for proteasomal degradation by delaying their delivery to the
proteasome.37 Presumably in such models, at the mechanistic
level proteostasis defects ultimately drive the accumulation of
proteins such as TARDBP in ALS and FTLD. If the model is
found to be viable, therapies directed at clearing excess




The plasmids for expression of full-length wild-type and G425R
mutant SQSTM1 protein (residues 1 to 440) as GST fusion proteins
(pGEX-4T-1; GE Healthcare, 28-9545-49) in E. coli have been
described previously.21,39,40 The L341V mutant construct was pro-
duced from the wild-type plasmid by site-directed mutagenesis
(QuikChange II kit; Agilent Technologies, 200523) and subse-
quently verified by DNA sequencing. The L341V mutation was
introduced into the wild-type pDEST-mCherry-EGFP-SQSTM1
construct15 via site-directed mutagenesis and verified by DNA
sequencing. Custom peptides (residues 332 to 351 of human
SQSTM1, SGGDDDWTHLSSKEVDPSTG (WT LIR) and
SGGDDDWTHVSSKEVDPSTG (LIR [L341V]) were synthesized
by PeptideSynthetics with a purity of> 98%. The cDNA of human
LC3B was cloned into the pGEX-4T-3 plasmid (GE Healthcare,
28-9545-52) between the EcoRI and SaII cloning sites. The cDNA
of humanUBC [ubiquitin C] was cloned into pKK233-3 (Promega,
27-4935-01) between EcoR1 and HindIII sites. Both the LC3B and
ubiquitin were expressed by growing transformed BL21 (DE3) E.
coli cells in either M9 minimal media or LB as described
previously.41
Protein purification
Ubiquitin was expressed and purified as described previously.41
The unlabeled, 15N-labeled and 13C/15N doubly-labeled LC3B
was expressed as described previously for UBA domain con-
structs of SQSTM1.30,41 Thrombin cleavage was used to remove
the GST-tag from glutathione-Sepharose-immobilized LC3B
fusions. Purification of the eluted proteins using a salt gradient
(0 to 2 M NaCl) on a cationic column (GE Healthcare,
17115201) in 5 mM potassium phosphate, pH 7, allowed frac-
tions of purified LC3B to be concentrated by lyophilization.
Fractions were then subsequently desalted on a 5 £ 5 ml
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HiTrapTM desalting column (GE Healthcare, 17-1408-01) in
25 mM ammonium acetate before further lyophilization.
Ubiquitin and LC3B affinity isolation assays
Ubiquitin and LC3B affinity isolation assays of GST-SQSTM1 pro-
teins were performed as described previously.40 Briefly, the GST
fusion proteins were expressed in 10 ml cultures of E. coli and cells
were lysed by sonicating in 1 ml TBS-T buffer (10 mM Tris,
150 mM NaCl, 0.1% v/v Triton-X100 [Thermo ScientificTM,
85112], pH 7.5). The lysed cells were centrifuged at 16060 g for
10 min at room temperature and the cleared supernatant fractions
were diluted 1:10 in TBS-T buffer. One ml of each diluted lysate
was incubated at 37C with excess glutathione-Sepharose (GE
Healthcare, 17-0756-01), ubiquitin-Sepharose (10 mg/ml human
ubiquitin immobilized on CNBr-activated Sepharose 4B [Sigma-
Aldrich, C9142]), LC3B-Sepharose (1 mg/ml LC3B immobilized
on CNBr-activated Sepharose 4B) or control-Sepharose (CNBr-
activated Sepharose prepared without ubiquitin or LC3B). The
unbound proteins were then removed and the beads washed with
3 £ 1 ml TBS-T buffer at 37C. Bound proteins were eluted from
the beads with 50 ml of SDS PAGE loading buffer (10% 2-mercap-
toethanol, 3% DTT, 20% glycerol, 2.5% SDS, 0.15 M Tris, 8 M
urea, 0.1% bromophenol blue, pH 6.8). Bound proteins were
revealed by western blotting with the mouse anti-SQSTM1 lck
ligand antibody (BD Biosciences, 610833) which is insensitive to
SQSTM1 UBA domain mutation status. Each assay was repeated
on a minimum of 3 independent occasions and representative
examples are presented. Immunoreactive bands were quantified by
densitometry of 3 independent blots using Fiji (ImageJ); lanes were
plotted and the area of intensity for each band quantified. The con-
trol-Sepharose values were subtracted from the glutathione-,
LC3B- and ubiquitin-Sepharose values for each SQSTM1 sequence
to account for nonspecific binding. LC3B- or ubiquitin-Sepharose
values were divided by the respective glutathione-Sepharose values
to normalize. Normalized values for the 2 GST-SQSTM1 mutants
were then divided by the value for the wild type. GraphPad Prism 6
was used for statistical analysis in which a 2-way ANOVAwith the
Dunnett multiple comparisons test was performed to determine
significance (significance set at 0.05).
Electrospray ionization mass spectrometry (ESI-MS)
competition assays
Native electrospray ionization mass spectrometry experiments
(ESI-MS) described in this study, were performed using a
Waters (Altrincham, UK) SYNAPT HDMSTM, a hybrid quad-
rupole-ion mobility-orthogonal acceleration TOF instrument
(oa-TOF). Three replicates of 6 titration samples were prepared
as equal (v/v) solution mixtures in 25 mM ammonium acetate
(pH 7) to the final concentrations of LC3B (5 mM) to each of
the SQSTM1 LIR peptides (WT LIR and LIR [L341V]); 5 mM).
The mixtures were directly infused into the mass spectrometer
at a flow rate of 5 mL/min using a syringe pump (Harvard
22 dual syringe pump, model 55-2222 Holliston, MA, USA)
and a 100 mL Hamilton syringe (Bonaduz, Switzerland). The
mass spectrometer was operated in positive ion mode under
the following optimized conditions: capillary voltage, 2.5 kV,
cone voltage, 40 V, trap CE, 8 V, transfer CE, 5 V, backing
pressure, »3.8 mbar, trap pressure, 2.1 £ 10¡2, TOF pressure.
A quadrupole profile was applied which gave optimal ion trans-
mission between 1000 to 4000 m/z. Spectra were acquired
between 500 to 4000 m/z for 2 min. Instrument control as well
as data processing was performed using MassLynxTM 4.1 soft-
ware. Spectra were generated from the raw data acquired.
Isothermal titration calorimetry (ITC)
Methods for isothermal titration calorimetry (ITC) have been
described previously.41,42 In brief ITC was carried out using a
MicroCal VP-ITC instrument. Ten ml of WT LIR or LIR (L341V)
stock solution (350 mM) in 25 mM phosphate buffer, 150 mM
NaCl, pH 7.5, was sequentially injected into the ITC cell containing
30mMLC3B at 298 K in the same buffer solution, and the exother-
mic heat pulse was measured. Data were corrected for the effects of
buffermixing by including an enthalpy ofmixing as an iterated var-
iable. The data were analyzed using the MicroCal Origin software
to determine a Kd using a global fit standard nonlinear least-
squares regression analysis.
Protein NMR experiments
3D NMR backbones assignments of LC3B (1H, 13Ca, 13Cb and
15N for > 95% of non-prolyl residues) were carried out on
Bruker AV(III)800 (Bruker UK Limited, Coventry, UK) and
Bruker AV(III)600 NMR (Bruker UK Limited, Coventry, UK)
spectrometers with a QCI cryoprobe and TXI room tempera-
ture probes respectively. Standard Bruker pulse sequences with
Watergate solvent suppression at 298 K were used on a 13C,
15N isotopically labeled LC3B sample of 1 mM concentration
in NMR buffer solution consisting of 25 mM potassium phos-
phate buffer, 50 mM NaCl, 5% (v/v) D2O (Sigma-Aldrich,
151882), 0.02% (w/v) sodium azide, pH 7.0. The assignment
was achieved using a combination of 2D and 3D experiments
(15N-HSQC, HNCO, HN(CA)CO, HNCA, HN(CO)CA,
HNCACB and HN(CO)CACB) using established assignment
procedures.
NMR titration experiments were executed solely on the
Bruker AV(III)800 NMR spectrometer using a QCI cryoprobe
and standard pulse sequences with watergate solvent suppres-
sion. NMR titration studies of 15N-labeled LC3B (0.25 mM)
with unlabeled LIR-peptides (WT LIR or LIR [L341V]) were
performed at 298 K and 1H-15N-HSQC spectra were collected
up to a LIR:LC3B ratio of 2:1 (i.e. up to 0.5 mM LIR). All NMR
data was processed with TopSpin 3.1 (Bruker) and analysis and
assignment was carried out in CcpNmr analysis 2.1.5 soft-
ware.43 Chemical shift perturbations were calculated as
DdHSQC D [(DdH)2 C (DdN/5)2]1/2,44 where DdH and DdN are
the observed shift perturbations in the 1H and 15N dimension
of the HSQC spectrum.
Fluorescence microscopy analyses
For live cell imaging the motor neuron-like cell line NSC-34
(a kind gift from Dr. Neil Cashman, University of Sheffield), a
hybrid line produced by fusion of neuroblastoma with mouse
motor neuron-enriched primary spinal cord cells,45 and the
mouse neuroblastoma cell line Neuro-2a (a kind gift from
AUTOPHAGY 1101
Dr. Lynn Bedford, University of Nottingham) were used. Cells
were cultured in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich, D6429) supplemented with 1% (v/v) penicil-
lin/streptomycin (Sigma-Aldrich, P0781) and 10% (v/v) FBS
(Sigma-Aldrich, F9665) and kept in humidified 37C, 5% CO2
incubators. Undifferentiated NSC-34 or Neuro-2a cells grown
in glass bottom dishes (WillCo) were transfected using Lipo-
fectamine 3000 (InvitrogenTM, L3000-08) according to manu-
facturer’s instructions with pDEST-mCherry-EGFP-SQSTM1
constructs (wild type or the L341V mutant). Thirty-two h after
transfection cells were treated with C/¡20 nM BafA1 (Calbio-
chem, 196000). Sixteen h later the media was removed from
the cells, the cells were washed in PBS (Sigma-Aldrich, D8537)
and then placed in Ringer buffer (2 mM CaCl2, 10 mM glucose,
10 mM HEPES, 5 mM KCl, 2 mM MgCl2¢6H2O, 155 mM
NaCl, 2 mM NaH2PO4¢H2O, pH 7.2) and directly examined by
wide-field fluorescence microscopy at 37C for up to one h.
Cells undergoing rapamycin treatment were treated as for cells
without BafA1 but with 20 nM rapamycin (VIVA Bioscience
Ltd., VB2112) added 3 h prior to imaging. Z-stacks were col-
lected (200 nm spacing) using a DeltaVision Elite microscopy
system (GE Healthcare Life Sciences, Buckinghamshire, UK)
with a x60, 1.42 numerical aperture objective (Olympus, South-
end-on-Sea, UK), images were recorded on a Photometric
CoolSnap camera (Photometrics, Arizona, USA). The live cell
filter wheel was used with the Quad-mCh polychroic. EGFP
fluorescence was excited at 475 nm (bandwidth 28 nm) and the
emission was recorded at 525 nm (bandwidth 25 nm). mCherry
fluorescence was excited at 575 nm (bandwidth 25 nm) and the
emission recorded at 632 nm (bandwidth 60 nm). Images of
GFP and mCherry fluorescence were acquired sequentially for
each z-stack slice. Single-cell image stacks underwent iterative
restoration in either Volocity (Perkin Elmer) or Huygens Pro-
fessional (Scientific Volume Imaging). Volocity was used to
determine a Pearson correlation coefficient (PCC) value for
each cell using the Costes method for estimating thresholds.46
Images of each condition were taken on a minimum of 3 inde-
pendent occasions and a minimum of 50 cells per condition
were analyzed. For every cell analyzed the PCC value was indi-
vidually determined and the mean PCC values were calculated
for all cells in each condition. GraphPad Prism 6 was used to
determine if the PCC values between different conditions were
statistically different using a one-way ANOVA analysis with
multiple comparisons test comparing the mean of each column
with the mean of every other column to report a multiplicity
adjusted P value for each comparison (significance set at 0.05).
Western blotting for autophagy markers
HeLa and NSC-34 cells were seeded at a density of 2 £ 105 cells/
well in 12-well plates. Twenty-four h later cells were treated with
varying concentrations of BafA1 (0, 1, 10 and 20 nM). Sixteen h
after treatment the media was removed from the cells, the cells
were washed in PBS and then harvested in fresh PBS. Cells were
then pelleted at 380 g for 5 min in a table-top centrifuge and the
PBS was removed. Cells were lysed in 300 mL of RIPA buffer
(150 mM NaCl, 1% IGEPAL CA-630 [Sigma-Aldrich, I8896],
0.5% sodium deoxycholate [Sigma-Aldrich,D6750], 0.1% SDS
[Fisher Scientific, BP166], 50 mMTris, pH 8.0, including protease
[Sigma-Aldrich, P8340] and phosphatase [Sigma-Aldrich, P5726]
inhibitors [at a 1:1000 dilution]). A BCA assay (ThermoFisher
Scientific, 23225) determined the total protein concentration of
each lysate and then lysates were separated by SDS PAGE on a 5–
20% acrylamide gels with 20 mg of total protein loaded per well.
Gels were transferred overnight and autophagy marker proteins
were revealed by western blotting with the mouse anti-SQSTM1
lck ligand antibody, rabbit anti-SQSTM1 antibody (Enzo Life Sci-
ences, BML-PW9860) and rabbit anti-LC3B antibody (MBL
International, PM036). The blots were also stained for ACTB/
b-actin (Sigma-Aldrich, A1978) to confirm equal protein loading.
Abbreviations
ALS amyotrophic lateral sclerosis
MAP1LC3B/LC3B microtubule-associated protein 1 light
chain 3 b (a mammalian ortholog of yeast
Atg8)
CSP chemical shift perturbation
EGFP enhanced green fluorescent protein
ESI-MS electrospray ionization mass spectrometry
FTLD frontotemporal lobar degeneration
HSQC heteronuclear single quantum correlation
ITC isothermal titration calorimetry
KIR KEAP1 interacting region
LIR LC3-interacting region
NMR nuclear magnetic resonance
PDB Paget disease of bone 1
PB1 phox and bem1 domain
PBS phosphate-buffered saline
PCC Pearson correlation coefficient
SOD1 superoxide dismutase 1, soluble
SQSTM1/p62 sequestosome 1
TARDBP/TDP-43 TAR DNA binding protein
UBA ubiquitin-associated domain
WT wild type
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